Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro - PubMed (original) (raw)
Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro
Mie Hirohata et al. Neuropharmacology. 2008 Mar.
Abstract
The aggregation of alpha-synuclein (alphaS) in the brain has been implicated as a critical step in the development of Lewy body diseases (LBD) [Parkinson's disease (PD)/dementia with Lewy bodies (DLB)] and multiple system atrophy (MSA). The involvement of neuroinflammation and microglial activation has been emphasized in the pathogenesis of PD. Recent epidemiological studies have revealed that therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing PD. Here, we examined the effects of NSAIDs, such as ibuprofen, aspirin, acetaminophen, meclofenamic acid sodium salt, sulindac sulfide, ketoprofen, flurbiprofen, diclofenac sodium salt, naproxen, and indomethacin, on the formation and destabilization of alphaS fibrils (falphaS) at pH 7.5 and 37 degrees C in vitro, using fluorescence spectroscopy with thioflavin S and electron microscopy. All examined NSAIDs, except for naproxen and indomethacin, inhibited the formation of falphaS in a dose-dependent manner. Moreover, these molecules dose-dependently destabilized preformed falphaS. The overall activity was in the order: ibuprofen approximately aspirin approximately acetaminophen approximately meclofenamic acid sodium salt approximately sulindac sulfide>ketoprofen approximately flurbiprofen approximately diclofenac sodium salt>naproxen approximately indomethacin. These findings indicate that NSAIDs could be key molecules for the development of therapeutic or preventive agents for LBD and MSA.
Similar articles
- Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro.
Hirohata M, Ono K, Naiki H, Yamada M. Hirohata M, et al. Neuropharmacology. 2005 Dec;49(7):1088-99. doi: 10.1016/j.neuropharm.2005.07.004. Epub 2005 Aug 25. Neuropharmacology. 2005. PMID: 16125740 - Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Ono K, Hirohata M, Yamada M. Ono K, et al. J Neurosci Res. 2007 May 15;85(7):1547-57. doi: 10.1002/jnr.21271. J Neurosci Res. 2007. PMID: 17387689 - Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.
Ono K, Hirohata M, Yamada M. Ono K, et al. Exp Neurol. 2007 Jun;205(2):414-24. doi: 10.1016/j.expneurol.2007.03.002. Epub 2007 Mar 7. Exp Neurol. 2007. PMID: 17425956 - Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
Ono K, Hirohata M, Yamada M. Ono K, et al. Curr Pharm Des. 2008;14(30):3247-66. doi: 10.2174/138161208786404191. Curr Pharm Des. 2008. PMID: 19075704 Review. - Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds.
Hirohata M, Ono K, Yamada M. Hirohata M, et al. Curr Pharm Des. 2008;14(30):3280-94. doi: 10.2174/138161208786404173. Curr Pharm Des. 2008. PMID: 19075706 Review.
Cited by
- NSAIDs in the treatment and/or prevention of neurological disorders.
Khansari PS, Coyne L. Khansari PS, et al. Inflammopharmacology. 2012 Jun;20(3):159-67. doi: 10.1007/s10787-011-0116-2. Epub 2012 Jan 10. Inflammopharmacology. 2012. PMID: 22231719 Review. - Sulindac for stroke treatment: neuroprotective mechanism and therapy.
Modi JP, Prentice H, Wu JY. Modi JP, et al. Neural Regen Res. 2014 Dec 1;9(23):2023-5. doi: 10.4103/1673-5374.147919. Neural Regen Res. 2014. PMID: 25657710 Free PMC article. No abstract available. - The role of glia in α-synucleinopathies.
Fellner L, Stefanova N. Fellner L, et al. Mol Neurobiol. 2013 Apr;47(2):575-86. doi: 10.1007/s12035-012-8340-3. Epub 2012 Sep 2. Mol Neurobiol. 2013. PMID: 22941028 Free PMC article. Review. - Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.
Fellner L, Jellinger KA, Wenning GK, Stefanova N. Fellner L, et al. Acta Neuropathol. 2011 Jun;121(6):675-93. doi: 10.1007/s00401-011-0833-z. Epub 2011 May 12. Acta Neuropathol. 2011. PMID: 21562886 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources